Korean Journal of Schizophrenia Research (대한조현병학회지)

Korean Society for Schizophrenia Research (대한조현병학회)
권호 표지
DOI QR코드

DOI QR Code

Change of Prescribing Pattern after Clozapine Discontinuation: A Retrospective Chart Review

클로자핀 중단 이후 처방 패턴의 변화: 후향적 의무기록 분석

  • Kang, Shi Hyun (Department of Social Psychiatry and Rehabilitation, National Center for Mental Health)
  • 강시현 (국립정신건강센터 정신사회재활과)
  • Received : 2020.11.26
  • Accepted : 2020.02.05
  • Published : 2021.04.30
⟨ Previous Next ⟩

Abstract

Objectives: Despite the high discontinuation rate of clozapine in refractory schizophrenia, there is limited evidence regarding the suggested treatment after clozapine discontinuation. Methods: The medical records of 37 patients who discontinued clozapine were retrospectively reviewed. The prescription patterns of antipsychotics, mood stabilizers, and antidepressants were compared at three points before and after clozapine treatment and at the most recent visit. Results: After clozapine discontinuation, 75.6% of the subjects were receiving antipsychotic polypharmacy, and 32.4% were taking more than 3 antipsychotics. The frequently used antipsychotics were olanzapine (21.5%), quetiapine (21.5%), and paliperidone (12.7%). The rates of augmentation with mood stabilizers and antidepressants were 43.2% and 29.7%, respectively. Furthermore, valproate was the most commonly used mood stabilizer (87.5%). Conclusion: Antipsychotic polypharmacy and augmentation are inevitable in schizophrenia patients for whom clozapine has been discontinued. Further research is required to improve the outcomes of polypharmacy and augmentation in schizophrenia patients.

Keywords

Acknowledgement

국립정신건강센터 임상연구사업(2020-03)으로 지원된 연구임.

References

  1. National Collaborating Centre for Mental Health (UK) Psychosis and Schizophrenia in Adults: Treatment and Management: Updated Edition 2014. London: National Institute for Health and Care Excellence (UK);2014.
  2. McIlwain ME, Harrison J, Wheeler AJ, Russell BR. Pharmacotherapy for treatment-resistant schizophrenia. Neuropsychiatr Dis Treat 2011;7:135-149. https://doi.org/10.2147/NDT.S12769
  3. Lewis SW, Barnes TR, Davies L, Murray RM, Dunn G, Hayhurst KP, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 2006;32:715-723. https://doi.org/10.1093/schbul/sbj067
  4. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006;163:600-610. https://doi.org/10.1176/appi.ajp.163.4.600
  5. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223. https://doi.org/10.1056/NEJMoa051688
  6. Wheeler A, Humberstone V, Robinson G. Outcomes for schizophrenia patients with clozapine treatment: how good does it get? J Psychopharmacol 2009;23:957-965. https://doi.org/10.1177/0269881108093588
  7. Duggan A, Warner J, Knapp M, Kerwin R. Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK. Br J Psychiatry 2003;182:505-508. https://doi.org/10.1192/bjp.182.6.505
  8. Brunette MF, Drake RE, Xie H, McHugo GJ, Green AI. Clozapine use and relapses of substance use disorder among patients with cooccurring schizophrenia and substance use disorders. Schizophr Bull 2006;32:637-643. https://doi.org/10.1093/schbul/sbl003
  9. Porcelli S, Balzarro B, Serretti A. Clozapine resistance: augmentation strategies. Eur Neuropsychopharmacol 2012;22:165-182. https://doi.org/10.1016/j.euroneuro.2011.08.005
  10. Siskind D, Siskind V, Kisely S. Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-Analysis. Can J Psychiatry 2017;62:772-777. https://doi.org/10.1177/0706743717718167
  11. Wagner E, Lohrs L, Siskind D, Honer WG, Falkai P, Hasan A. Clozapine augmetation strategies-a systematic meta-review of available evidence. Treatment options for clozapine resistance. J Psychopharmacol 2019;33:423-435. https://doi.org/10.1177/0269881118822171
  12. Muscatello MRA, Bruno A, Fazio PD, Segura-Garcia C, Fandolfo G, Zoccali R. Augmentation strategies in partial responder and/or treatment-resistant schizophrenia patients treated with clozapine. Expert Opin Pharmacother 2014;15:2329-2345. https://doi.org/10.1517/14656566.2014.956082
  13. Berardis DD, Rapini G, Olivieri L, Nicola DD, Tomasetti C, Valchera A, et al. Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine. Ther Adv Drug Saf 2018;9:237-256. https://doi.org/10.1177/2042098618756261
  14. Hayhurst KP, Brown P, Lewis SW. The cost-effectiveness of clozapine: a controlled, population-based, mirror-image study. J Psychopharmacology 2002;16:169-175. https://doi.org/10.1177/026988110201600208
  15. Kang SH, Lee HW. Prescribing pattern of clozapine and clinical factors associated with discontinuation of clozapine. Korean J Schizophr Res 2019;22:1-7. https://doi.org/10.16946/kjsr.2019.22.1.1
  16. Gallego JA, Bonetti J, Zhang J, Kane JM, Correll CU. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional tends from 1970s to 2009. Schizophr Res 2012;138:18-28. https://doi.org/10.1016/j.schres.2012.03.018
  17. Chang JG, Roh DY, An SK, Cho HS, Kim CH. Antipsychotic polypharmacy in the treatment of patients with related psychosis at a university hostipal. Korean J Psychopharmacol 2013;24:69-75.
  18. Yun JY, Lee JS, Kang SH, Nam BW, Lee SJ, Lee SH, et al. Korean treatment guideline on pharmacotherapy of co-existing symptoms and antipsychotics-related side effects in patients with schizophrenia. Korean J Schizophr Res 2019;22:21-33. https://doi.org/10.16946/kjsr.2019.22.2.21
  19. Lee JS, Yun JY, Kang SH, Lee SJ, Choi JH, Nam BW, et al. Korean Medication Algorithm for Schizophrenia 2019, Second Revision: Treatment of Psychotic Symptoms. Clin Psychopharmacol Neuroscience 2020;18:386-394. https://doi.org/10.9758/cpn.2020.18.3.386
  20. Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull 2009;35:443-457. https://doi.org/10.1093/schbul/sbn018
  21. Galling B, Roldan A, Hagi K, Rietschel L, Walyzada F, Zheng W, et al. Antipsychotic augmentation vs monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World Psychiatry 2017;16:77-89. https://doi.org/10.1002/wps.20387
  22. Guinart D, Correll CU. Antipsychotic polypharmacy in schizophrenia: why not? J Clin Psychiatry 2020;83:3.
  23. Sinclair D, Adams CE. Treatment resistant schizophrenia: a comprehensive survey of randomised controlled trials. BMC Psychiatry 2014;12:253. https://doi.org/10.1186/s12888-014-0253-4
  24. Dold M, Leucht S. Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective. Evid Based Ment Health. May 2014;17:33-37. https://doi.org/10.1136/eb-2014-101813
  25. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 2012;13:318-378. https://doi.org/10.3109/15622975.2012.696143
  26. Luykx JJ, Stam N, Tanskanen A, Tiihonen J, Taipale H. In the aftermath of clozapine discontinuation: comparative effectiveness and safety of antipsychotics in patients with schizophrenia who discontinue clozapine. Br J Psychiatry 2020;217:498-505. https://doi.org/10.1192/bjp.2019.267
  27. Mao YM, Zhang MD. Augmentation with antidepressants in schizophrenia treatment: benefit or risk. Neuropsychiatr Dis Treat 2015;11:701-713. https://doi.org/10.2147/NDT.S62266
  28. Helfer B, Samara MT, Huhn M, Klupp E, Leucht C, Zhu Y, et al. Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis. Am J Psychiatry 2016;173:876-886. https://doi.org/10.1176/appi.ajp.2016.15081035